3 Euronext Paris Stocks Estimated To Be Trading Up To 49.2% Below Intrinsic Value

In This Article:

As global markets react to the recent U.S. Federal Reserve rate cut, European indices have shown mixed results, with France's CAC 40 Index posting modest gains. Amid this evolving economic landscape, identifying undervalued stocks becomes crucial for investors seeking potential opportunities. In the current market conditions, a good stock is often characterized by strong fundamentals and trading below its intrinsic value. Here are three Euronext Paris stocks estimated to be trading up to 49.2% below their intrinsic value, offering potential for significant upside as market dynamics unfold.

Top 10 Undervalued Stocks Based On Cash Flows In France

Name

Current Price

Fair Value (Est)

Discount (Est)

Cogelec (ENXTPA:ALLEC)

€11.70

€23.14

49.4%

NSE (ENXTPA:ALNSE)

€30.00

€57.47

47.8%

Vivendi (ENXTPA:VIV)

€10.37

€18.06

42.6%

Eurobio Scientific Société anonyme (ENXTPA:ALERS)

€25.00

€49.20

49.2%

Guillemot (ENXTPA:GUI)

€5.24

€9.44

44.5%

Lectra (ENXTPA:LSS)

€29.10

€53.58

45.7%

Groupe Berkem Société anonyme (ENXTPA:ALKEM)

€3.05

€5.09

40.1%

Vogo (ENXTPA:ALVGO)

€3.19

€6.37

49.9%

Solutions 30 (ENXTPA:S30)

€1.401

€2.51

44.2%

VusionGroup (ENXTPA:VU)

€151.60

€257.62

41.2%

Click here to see the full list of 22 stocks from our Undervalued Euronext Paris Stocks Based On Cash Flows screener.

Here's a peek at a few of the choices from the screener.

Eurobio Scientific Société anonyme

Overview: Eurobio Scientific Société anonyme designs, develops, and commercializes in vitro diagnostics products for transplantation, immunology, infectious diseases, life-science, and cancer; it has a market cap of €251.09 million.

Operations: Eurobio Scientific Société anonyme generates €130.65 million from its Diagnostics and Therapeutics segment.

Estimated Discount To Fair Value: 49.2%

Eurobio Scientific Société anonyme is trading at €25, significantly below its estimated fair value of €49.2. Recent earnings for the half year ended June 30, 2024, showed sales rising to €73.11 million from €58.99 million a year ago and net income doubling to €4 million. Despite improved revenue and profit margins, the stock remains highly undervalued based on discounted cash flow analysis, with earnings forecasted to grow 31.6% annually over the next three years.

ENXTPA:ALERS Discounted Cash Flow as at Sep 2024
ENXTPA:ALERS Discounted Cash Flow as at Sep 2024

Safran

Overview: Safran SA, with a market cap of €89.62 billion, operates globally in the aerospace and defense sectors through its subsidiaries.